COMP <GO>
VKTX vs LLY // EV/EBITDA & P/E VALUATION
Viking Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: VKTX 3
— LLY 11
■ METRIC PARITY
LAST: $27.28 (+1.56%) • MKT CAP: $3.38B
valuation
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VKTX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VKTX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 83.64% | -39.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.25% | 2.30% | -10.55 | LLY | /fcf-yield <GO> |
| Operating Margin | 16.50% | 40.21% | -23.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 31.90% | -19.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 45.51% | -30.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.02 | 9.29 | +14.73 | VKTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | VKTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 77.9 | -29.90 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.51 | +0.40 | VKTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 26.3x | +8.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.38B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VKTX REV | LLY REV | VKTX GROSS % | LLY GROSS % | VKTX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$278.7M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$87.8M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$73.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VKTX // BETA 0.91
LLY // BETA 0.51